Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Carolin SengerA ContiA KlugeD PasemannM KufeldG AckerM LukasA GrünG KalinauskaiteV BudachJ WaiserC StrombergerPublished in: BMC urology (2019)
Robotic SABR is technically feasible for the treatment of RCC in preexisting kidney disease with good local tumor control at about 2 years follow-up. Robotic SABR with motion tracking offers a valid treatment option for patients, who are at increased risk for progression to end-stage renal disease due to partial nephrectomy or ablative techniques.